• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Differin (adapalene gel) Gel, 0.1%

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Differin (adapalene gel) Gel, 0.1%

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Differin Gel 0.1% has been approved for the treatment of acne. Differin Gel is a new topical prescription medication that penetrates deeply into hair follicles where it can prevent and reduce blackheads and whiteheads.

    Clinical Results

    In controlled clinical trials, Differin Gel was shown to effectively reduce the number and severity of acne lesions after 12 weeks of therapy. Furthermore, the subjects on Differin Gel experienced less skin dryness and skin irritation than those on topical Tretinoin Gel 0.025%. Stinging, burning, peeling, and skin redness associated with retinoid therapy have been a barrier to subjects remaining on their Tretinoin acne medication and achieving successful treatment outcomes.

    Side Effects

    Some adverse effects such as erythema, scaling, dryness, pruritus, and burning will occur in 10%-40% of subjects. Pruritus or burning immediately after application also occurs in approximately 20% of subjects. The following additional adverse experiences were reported in approximately 1% or less of subjects: skin irritation, burning/stinging, erythema, sunburn, and acne flares. These are most commonly seen during the first month of therapy and decrease in frequency and severity thereafter.

    Mechanism of Action

    Differin Gel is a synthetic retinoid analogue with advanced receptor selective activity and potent anti-inflammatory and comedolytic properties.

    Literature References

    Shalita, Weiss, Chalker, et al. "A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne and vulgaris: A multicentre trial." Journal of the American Academy of Dermatology. March, 1996.

    Approval Date: 1996-06-01
    Company Name: Galderma Laboratories
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing